VEGF-C Protects the Integrity of Bone Marrow Perivascular Niche. Blood [Internet]. 2020;:accepted - for publication. https://ashpublications.org/blood/article/doi/10.1182/blood.2020005699/463465/VEGF-C-Protects-the-Integrity-of-Bone-Marrow

Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1. Scientific Reports [Internet]. 2017;7(1):4916. https://www.nature.com/articles/s41598-017-04982-1

Functional Dissection of the CCBE1 Protein: A Crucial Requirement for the Collagen Repeat Domain. Circ Res [Internet]. 2015;116(10):1660-1669. http://circres.ahajournals.org/content/116/10/1660.long

The TIE Receptor Family. In Receptor Tyrosine Kinases: Family and Subfamilies [Internet]. Springer International Publishing; 2015. S. 743-775. https://link.springer.com/content/pdf/10.1007%2F978-3-319-11888-8_16.pdf

CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation. Circulation [Internet]. 2014;129(19). http://circ.ahajournals.org/content/early/2014/02/19/CIRCULATIONAHA.113.002779.abstract

The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands. Sci Signal. 2013;6(282):ra52. 

Receptor Tyrosine Kinase-Mediated Angiogenesis. Cold Spring Harbor Perspectives in Biology [Internet]. 2013;5(9). http://cshperspectives.cshlp.org/content/5/9/a009183

Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2013;110(32):12960 - 12965. http://www.pnas.org/content/110/32/12960.long

Leppänen V-M, Jeltsch M, Anisimov A, Tvorogov D, Aho K, Kalkkinen N, u. a.. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood [Internet]. 2011;117(5):1507 - 15. http://view.ncbi.nlm.nih.gov/pubmed/21148085

Tvorogov D, Anisimov A, Zheng W, Leppänen V-M, Tammela T, Laurinavicius S, u. a.. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell [Internet]. 2010;18(6):630 - 40. http://view.ncbi.nlm.nih.gov/pubmed/21130043

Leppänen V-M, Prota AE, Jeltsch M, Anisimov A, Kalkkinen N, Strandin T, u. a.. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2010;107(6):2425 - 30. http://view.ncbi.nlm.nih.gov/pubmed/20145116

Anisimov A, Alitalo A, Korpisalo P, Soronen J, Kaijalainen S, Leppänen V-M, u. a.. Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ Res [Internet]. 2009;104(11):1302 - 12. http://view.ncbi.nlm.nih.gov/pubmed/19443835